Urticaria and Angioedema

2. Auflage 2021
ISBN: 978-3-030-84576-6
Verlag: Springer International Publishing

Buch, Englisch, 251 Seiten, Paperback, Format (B × H): 155 mm x 235 mm, Gewicht: 454 g

Urticaria is one of the most common diseases encountered in dermatology. The fleeting nature of wheals often makes a first diagnosis by both patients and physicians seem easy. The disease itself is of a highly complex nature, with a variety of clinical manifestations ranging from pinpoint sized wheals to extensive angioedema. Further complexities include the diversity of possible eliciting and aggravating factors, the many different clinical subtypes and the therapeutic responsiveness.

This second, extensively revised edition includes the indications listed in the most recent international guidelines, provides a practical, comprehensive review of all clinical aspects and causes, and addresses the diagnosis and therapy of different types of urticaria. Specific chapters are devoted to classification, aetiopathogenesis, patient reported outcomes, acute urticaria, chronic urticaria and its comorbidities, angioedema without weals, inducible urticarias, special populations including children, treatment with antihistamines and omalizumab, other interventions and looking ahead to new therapies. This new edition is a must read for dermatologists, allergists, pediatricians and practitioners of all disciplines who want their patients to benefit from cutting-edge diagnostics and treatments.

Zielgruppe

Professional/practitioner

Autoren/Hrsg.

Zuberbier, Torsten

Maurer, Marcus

Grattan, Clive

Fachgebiete

• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Pädiatrie, Neonatologie
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Dermatologie
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Innere Medizin
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Allergologie

Inhaltsverzeichnis

1. History of Urticaria2. Aetiopathogenesis of urticaria3. Classification and diagnosis of Urticaria4. Impact of chronic urticaria and how to measure it5. Acute Urticaria6. Chronic spontaneous Urticaria 7. Chronic spontaneous urticaria & co-morbidities8. Inducible urticarias9. Angioedema10. Management principles in urticaria11. Antihistamines12. Omalizumab in the treatment of urticaria 13. Other interventions for chronic urticaria14. Urticaria in pediatrics and during pregnancy and lactation: highlights on epidemiology, diagnosis and management 15. Urticaria Therapy and Management. Looking Forward

Über Autor(innen)

Torsten Zuberbier is Professor at Charité Berlin and President of the Global Allergy and Asthma European Network (GA²LEN). In addition, he is chairman of the European Centre for Allergy Research Foundation (ECARF). Prof. Zuberbier completed his clinical and scientific education in the field of dermatology at the Charité Virchow Klinikum and wrote his post-doctoral dissertation on the differentiation and function of human mast cells. In 2003, he was appointed Head of Allergy and Co-Director of the Department of Dermatology and Allergy at the Charité Berlin. Prof. Zuberbier’s research focuses on urticaria since 1990, initiating systematic guidelines from 2000 onwards. Further research interest is, airways allergies, atopic eczema, food allergies and human mast cells. He has published more than 500 papers and is a member of numerous scientific bodies.

Clive Grattan, MA, MD, FRCP, is Consultant Dermatologist at St John’s Institute of Dermatology, London. He has led the difficult urticaria clinic at St Thomas’ Hospital for 15 years. He has had a clinical and research interest in urticaria since the 1980’s, including original studies on chronic autoimmune urticaria pathogenesis and management. He was the first to describe the autologous serum skin test response in chronic idiopathic urticarial and was awarded a Doctorate of Medicine by Cambridge University for his thesis. First author of the first revisions of the British Association of Dermatology guidelines on urticarial, he currently undertakes clinical research in chronic urticaria and mastocytosis and teaches extensively, has written many contributions and spoken on these topics worldwide. He has been EiC of Clinical and Translational Allergy, journal of the EAACI, was chairman of the Dermatology section and a member of the Executive Committee member of the EAACI, President of the Dermatology section of the R.S. of Medicine and a council member of the British Society of Allergy and Clinical Immunology. He has had longstanding involvement with the regulatory aspects of medicine doing committee work for the UK Health Dept., the Medicines Regulatory Healthcare Authority, the European Medicines Agency and the National Institute of Clinical Excellence. Current clinical practice includes all aspects of adult Dermatology with a special interest in Cutaneous Allergy.

Marcus Maurer is Professor of Dermatology and Allergy at the Allergie-Centrum-Charité in Berlin, Germany. He trained in dermatology and allergology in Berlin and Mainz, and in experimental pathology at the Beth Israel Deaconess Hospital and Harvard Medical School in Boston from 1995 to 1998, prior to attaining his board certification for dermatology in 2000 and allergology in 2003. He has made numerous important contributions to our understanding of the role of mast cells in the pathogenesis of chronic inflammatory disorders as well as in protection from infections. His clinical emphasis is on urticaria, pruritus, and auto-inflammatory syndromes. M. Maurer is the author of over 390 publications in peer-reviewed journals including Nature and the NEJ of Medicine. Over several years, Prof. Maurer’s team has established national reference centers for the investigation and treatment of urticaria, mastocytosis, hereditary angioedema, angioedema and other mast cell-driven diseases, and has conducted more than 30 randomized controlled trials (phase I through IV) since 2011.